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Abstract
Background: The pragmatic–explanatory continuum indicator summary version 2 (PRECIS-2) tool has recently been
developed to classify randomized clinical trials (RCTs) as pragmatic or explanatory based on their design characteristics.
Given that treatment effects in explanatory trials may be greater than those obtained in pragmatic trials, conventional
meta-analytic approaches may not accurately account for the heterogeneity among the studies and may result in
biased treatment effect estimates. This study investigates if the incorporation of PRECIS-2 classification of published
trials can improve the estimation of overall intervention effects in meta-analysis.
Methods: Using data from 31 published trials of intervention aimed at reducing obesity in children, we evaluated the
utility of incorporating PRECIS-2 ratings of published trials into meta-analysis of intervention effects in clinical trials.
Specifically, we compared random-effects meta-analysis, stratified meta-analysis, random-effects meta-regression, and
mixture random-effects meta-regression methods for estimating overall pooled intervention effects.
Results: Our analyses revealed that mixture meta-regression models that incorporate PRECIS-2 classification as covariate
resulted in a larger pooled effect size (ES) estimate (ES = − 1.01, 95%CI = [− 1.52, − 0.43]) than conventional random-effects
meta-analysis (ES = − 0.15, 95%CI = [− 0.23, − 0.08]).
Conclusions: In addition to the original intent of PRECIS-2 tool of aiding researchers in their choice of trial design, PRECIS-
2 tool is useful for explaining between study variations in systematic review and meta-analysis of published trials. We
recommend that researchers adopt mixture meta-regression methods when synthesizing evidence from explanatory and
pragmatic trials.
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Background
Randomized controlled trials (RCTs) are cited as the
highest level of evidence that can inform clinical and
policy decisions about the efficacy and/or effectiveness
of an intervention [1–3]. However, RCTs are generally
costly, with many stringent inclusion and exclusion cri-
teria which limit generalizability of results and relevance
to routine clinical practice. Consequently, there is in-
creased interest in designing RCTs that show real-world
effectiveness of an intervention in broad patient popula-
tions [4–7]. Schwartz and Lellouch [8] proposed a dis-
tinction between explanatory trials, which confirm a
physiological or clinical hypothesis, and pragmatic trials,
which inform a clinical or policy decision by providing
evidence for adoption of the intervention into real-world
clinical practice. Since their seminal paper, several pa-
pers have investigated the strengths and limitations of
pragmatic trials [4–12]. Thorpe et al. [13, 14] proposed
the original PRECIS (pragmatic–explanatory continuum
indicator summary) tool that further clarified the con-
cept and features of pragmatism and a scoring system
and visual representation of the graphical representation
of the pragmatic features of a trial. Loudon et al. [15, 16]
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later proposed a revision of the PRECIS, called PRECIS-
2, a 9-item tool to assess the characteristics of a prag-
matic design. Features of the PRECIS-2 tools include the
recruitment of investigators and participants, the inter-
vention and its delivery, follow-up, and the determin-
ation and analysis of outcomes. Many trials could be
deemed to be pragmatic with regard to at least one of
these dimensions, but few are truly pragmatic on all
dimensions.
A number of studies have explored the use of PRECIS
instruments when synthesizing evidence from published
trials. For example, Patsopoulos [17] suggests that “sys-
tematic reviews and meta-analyses could incorporate a
PRECIS score for synthesized trials and help the system-
atic mapping of the pragmatism in published research”.
Yoong et al. [18] investigated the impact of pragmatic–
explanatory study design characterization on conclusions
of systematic reviews of public health interventions of
obesity trials. They observed that there were no differ-
ences among the intervention effects across classifica-
tions of the synthesized studies based on PRECIS
ratings. Koppenaal et al. [19] applied a modified version
of PRECIS, called PRECIS review tool, to judge the
applicability of studies in systematic reviews for daily
clinical practice in two systematic reviews [19]. Tosh et
al. [20] proposed the pragmascope, an adapted version
of the PRECIS tool that uses a 5-point scale to assess the
degree of pragmatism when designing RCTs in mental
health. Witt et al. [21] conducted a systematic analysis
in trials of acupuncture for lower back pain with the
intention of applying the PRECIS tool. Glasgow et al.
[22] also used the PRECIS tool to describe the design
features of three effectiveness trials investigating weight
loss in obese patients with comorbid conditions. More
recently, Jordan et al. [23] also demonstrated the poten-
tial benefit of using the PRECIS-2 instrument for aiding
systematic review and meta-analysis of studies in hepa-
titis C virus care. Louma et al. [24] used PRECIS-2 to
identify interventions that effectively increased physical
activity and glycemic controls among patients with type
2 diabetes and assess the potential use of PRECIS-2 for
implementing physical activity interventions in clinical
practice settings.
While the uptake of PRECIS instruments (i.e., PRECIS
and PRECIS-2) in systematic reviews is increasing, these
instruments are mostly used descriptively but their
impact in explaining heterogeneity in meta-analytic
investigations has not been investigated. Given the varia-
tions in study designs, differences in study characteris-
tics of explanatory and pragmatic trials are likely to
influence both statistical heterogeneity and intervention
effect estimates in meta-analyses. Aves et al. [25] argues
that “….If heterogeneity is substantial, due to 66the de-
gree of pragmatism, it might not be appropriate to pool
data from pragmatic and explanatory trials….” Although
modern meta-analytic methods such as mixture meta-
regression and robust meta-analytic methods have been
developed to pool evidence from heterogeneous popula-
tions [26–28], there is limited application of these
methods and incorporation of PRECIS ratings in synthe-
sizing evidence from explanatory and pragmatic trials.
This study aimed to assess whether the incorporation
of PRECIS classification could improve the modeling of
heterogeneity among published trials in meta-analytic
investigations. Using data from a Cochrane systematic
review of 31 trials of community-based obesity interven-
tion in children [29], we compared the performance of
random-effects, stratified random-effects, and mixture
random-effects meta-regression techniques that
accounted for differences between explanatory and prag-
matic trials for synthesizing evidence from published
trials.
Methods
The pragmatic–explanatory continuum indicator
summary (PRECIS-2)
PRECIS was developed by a group of international
researchers and methodologists to assist trialists in
distinguishing between pragmatic and explanatory trial
designs [13, 14]. PRECIS requires trialists to indicate on
a visual scale (in the shape of wheel) where a trial falls
along the pragmatic–explanatory continuum. More
recently, a revision of the PRECIS tool, PRECIS-2, was
developed [15]. This consists of nine domains, including
eligibility, recruitment, setting, organization, flexibility in
intervention delivery, flexibility in adherence, follow-up,
primary outcome, and primary analysis. Each domain is
rated on a 5-point Likert scale from 1 (completely
explanatory) to 5 (completely pragmatic) [16].
Systematic review of obesity prevention trials
Data were from the Cochrane systematic review of trials
that investigated the efficacy or effectiveness of
community-based obesity prevention interventions in
children [29]. The systematic review included all RCTs
published between 1990 and March 2010. Similar to the
previous work by Yoong et al. [18], we used an adapted
version of the PRECIS-2 tool to conduct an audit of all
30 trials of children age 6–12 years included in the
Cochrane review of obesity trials to assess the prag-
matic–explanatory design features of these studies.
Raters and rating procedures
Before rating the trials in this systematic review, three
study co-authors (TTS, OA, MW) first read and dis-
cussed relevant papers on PRECIS [13–16] and piloted
their knowledge of the PRECIS tool using 5 randomly
selected published trials. Raters then independently rated
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each of the 31 trials on the 9 domains of the PRECIS-2
tools. Each domain was a score on a 5-point scale that
range from 1 (completely explanatory) to 5 (completely
pragmatic) using the broad definitions provided by the
tool developers [15, 16]. Authors then met to discuss
variations in scoring and reached a consensus where
there were discrepancies. For each investigator and each
trial, an overall summary score was derived by averaging
of the ratings of the 9 items. High scores indicated a
more pragmatic trial, while lower scores indicated the
trial is more explanatory. Since no cut-off scores were
provided by the original authors, we applied a scoring
method for categorizing the trials as explanatory or
pragmatic. Specifically, we classified a trial as explana-
tory if the average score for the trial is less than 3.0,
while a trial is considered pragmatic if the average
PRECIS-2 is at least 3.0.
Statistical analyses
Descriptive statistics was used to summarize the average
domain-specific and overall PRECIS-2 scores across the
31 studies included in this analysis. Fleiss kappa statistic
was used to assess inter-rater reliability among the
domain-specific and overall ratings of each trial on the
PRECIS-2 scale [30]. Four meta-analytic methods were
used to assess the changes in conclusions about overall
intervention effect on body mass index of these children.
These include (i) the conventional random-effects meta-
analysis; (ii) stratified random-effects meta-analysis, in
which effect sizes from pragmatic trials and explanatory
trials were independently pooled; (iii) random-effects
meta-regression that adjusted for PRECIS-2 rating
(explanatory vs pragmatic); and (iv) a mixture random-
effects meta-regression that adjusted for PRECIS-2
rating (pragmatic vs explanatory). For each model, we
report pooled effect size (ES), 95% confidence interval,
between-study variance (τ2), and Bayesian information
criterion. All analyses, including kappa estimated, were
conducted using R software [31].
Results
Of the 31 studies included in our analysis, 12 trials were
focused on physical activity interventions only, 5 focused
on dietary interventions only, while 14 adopted a com-
bination of physical and dietary interventions [29]. As
reported in the Cochrane review [29], the reported stan-
dardized mean difference in body mass index between
the intervention to reduce obesity in children and the
controls for these 31 trials ranged between − 0.36 and
0.45 (Fig. 1). The inter-rater reliability among our inde-
pendent raters, as measured by the Fleiss kappa, ranged
between 0.41 and 0.86, indicating moderate to substan-
tial agreement across the domains [30]. We achieved
moderate to substantial agreement for all the domains,
with flexibility (delivery) and follow-up domains showing
lower agreement (κ = 0.41 and 0.48, respectively). The
Fig. 1 Forest plot obesity trials of children aged 6–12
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Table 1 PRECIS-2 ratings and characteristics of 31 published trials of interventions to reduce obesity in children aged 6–12 years
Study Type of treatment Standardized mean
difference
Standard
error*
Average overall PRECIS
rating
PRECIS
classification
Baranowski 2003 (2) Physical activity and
dietary
0.99 0.388 2.44 Explanatory
Lazaar 2007 (6) Physical activity − 0.58 0.16 2.78 Explanatory
Lazaar 2007 (7) Physical activity − 0.75 0.16 2.78 Explanatory
Lazaar 2007 (8) Physical activity − 0.38 0.29 2.78 Explanatory
Lazaar 2007 (9) Physical activity − 0.48 0.29 2.78 Explanatory
Story 2003a (2) Physical activity and
dietary
− 0.56 0.28 3.22 Pragmatic
Beech 2003 (4) Physical activity and
dietary
− 0.52 0.41 3.11 Pragmatic
Caballero 2003 Physical activity and
dietary
− 0.05 0.05 3.00 Pragmatic
Robinson 2003 (2) Physical activity and
dietary
− 0.08 0.26 3.00 Pragmatic
Beech 2003 (5) Physical activity and
dietary
− 0.52 0.41 3.11 Pragmatic
Kain 2004 (1) Physical activity and
dietary
− 0.19 0.06 3.33 Pragmatic
James 2004 Dietary − 0.39 0.09 4.50 Pragmatic
Kain 2004 (2) Physical activity and
dietary
0.06 0.06 3.33 Pragmatic
Harrison 2006 Physical activity − 0.18 0.12 3.89 Pragmatic
Amaro 2006 Dietary − 0.19 0.14 3.11 Pragmatic
Spiegel-2006-
Obesity
Physical activity and
dietary
− 0.38 0.06 3.56 Pragmatic
Gutin 2008 Physical activity − 0.10 0.10 3.67 Pragmatic
Hamelink-Basteen Physical activity and
dietary
− 0.12 0.13 3.0 Pragmatic
Simon 2008 Physical activity − 0.02 0.07 4.33 Pragmatic
Reed 2008 Physical activity 0.04 0.14 3.89 Pragmatic
Foster 2008 Physical activity − 0.06 0.07 3.78 Pragmatic
Paineau 2008 (10) Dietary − 0.04* 0.09 3.00 Pragmatic
Vizcaino 2008 (2) Physical activity − 0.03* 0.09 3.00 Pragmatic
Sanigorski 2008 Physical activity and
dietary
− 0.17 0.05 4.25 Pragmatic
Taylor 2008 Physical activity and
dietary
− 0.39 0.10 3.00 Pragmatic
Paineau 2008 (11) Dietary − 0.02 0.09 3.00 Pragmatic
Vizcaino 2008 (1) Physical activity 0.00 0.09 3.00 Pragmatic
Gentile 2009 Physical activity and
dietary
0.04 0.06 4.00 Pragmatic
Sichieri 2009 Dietary 0.08 0.07 4.56 Pragmatic
Donnelly 2009 Physical activity 0.00 0.05 4.22 Pragmatic
Marcus 2009 Physical activity and
dietary
− 0.42 0.07 3.25 Pragmatic
*Rounded up to the nearest two decimal places
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average overall ratings ranged between 2.44 and 4.56.
Using a cut-off of 3.0, five studies were classified as ex-
planatory while the remaining 26 studies were classified
as pragmatic (see Table 1 and Fig. 2).
Table 2 and Fig. 3 describe the estimates of pooled
intervention effect size based on random-effects
meta-regression methods for 31 published trials. Con-
ventional pooling of the intervention effects across all
the studies based on random-effects meta-analysis
suggest statistically significant pooled ES of − 0.15
(95%CI = [− 0.23, − 0.08]). When we fitted stratified
meta-analysis independently for pragmatic and ex-
planatory trials, the meta-analysis of the explanatory
trials revealed no significant pooled intervention effect
for the explanatory trials (ES = − 0.32; 95%CI = [− 0.88,
0.33]) but statistically significant pooled intervention
effect for the pragmatic trials (ES = − 0.12; 95%CI = [−
0.19, − 0.06]). Nevertheless, the pooled intervention
effect from the explanatory trials was about 2.5 times
the pooled effect size obtained from the pragmatic
trials. Meta-regression methods that adjusted for
overall PRECIS-2 ratings revealed significantly larger
pooled effect sizes and smaller τ2 than the conven-
tional overall pooled effect size. Specifically, the
random-effects meta regression model that adjusted
for PRECIS-2 rating revealed a statistically significant
pooled effect size (ES = − 0.79, 95%CI = [− 1.26, − 0.31]
that is more than five times larger than the estimated
pooled effect size obtained from the conventional
meta-analysis model. The mixture random-effects
meta-regression model that controlled for PRECIS rat-
ing (pragmatic vs explanatory) even revealed substan-
tially large and statistically significant pooled effect
size (ES = − 1.05, 95%CI = [− 1.53, − 0.54]) (Fig. 3).
Discussion
The incorporation of PRECIS-2 classification of the trials
as covariate in meta-regression models results in larger
estimates of pooled intervention effects in published tri-
als than previously reported pooled effect sizes [19, 29].
Meta-regression methods, such as mixture regression
models that controls for PRECIS-2 rating as a covariate,
are particularly advantageous in that they can account
for heterogeneity among the studies by modeling the
heterogeneity attributable to pragmatism using mixture
distribution. This finding supports results from previous
research that recognize the importance of accounting for
between-study heterogeneity that is attributable to the
degree of pragmatism in systematic review of published
trials [18, 27]. It highlights the utility of PRECIS-2 tool
for aiding synthesis of evidence from published trials
and the impact of information that design characteristics
can have in explaining the between-study heterogeneity
when conducting meta-analysis of published studies. We
recommend that researchers should not only use
PRECIS-2 rating information descriptively in meta-
analysis of published studies but also for inferential pur-
poses for modeling heterogeneity when estimating
pooled intervention effects.
Fig. 2 Average PRECIS-2 wheel domain scores for pragmatic and
explanatory trial classification of 31 obesity trials in children
aged 6–12 years
Table 2 Comparison of meta-analytic methods for estimating overall intervention effect in trials to reduce obesity in children aged
6–12 years
Meta-analytic methods Pooled effect size 95%CI τ2 BIC
Random-effects meta-analysisa − 0.15 [− 0.23, − 0.08]* 0.029 8.08
Stratified meta-analysis
Explanatory trialsb − 0.32 [− 0.88, 0.33] 0.209 − 11.97
Pragmatic trialsb − 0.12 [− 0.19, − 0.06]* 0.018 − 9.74
Meta-regression methods
REMR controlling for PRECIS − 0.79 [− 1.26, − 0.29]* 0.020 − 5.33
Mixture REMR controlling for PRECIS − 1.01 [− 1.52, − 0.43]* 0.010 − 10.39
τ2 between-trial variance, BIC Bayesian information criterion, REMR random effects mixture regression, 95%CI 95% confidence interval
*p < 0.05
aUnadjusted model
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Also, we found that stratified meta-analytic methods,
in which explanatory and pragmatic trials are defined
with explicit criteria and independently synthesized, sup-
ported the notion that there was an overall significant
effect of the community-based obesity intervention in
children in pragmatic trials but not in explanatory trials.
The estimated pooled effect size obtained from synthesis
of pragmatic trials was significantly smaller than the esti-
mated pooled effect size obtained from synthesis of ex-
planatory trials. This finding is in line with previous
research that shows explanatory trials often report larger
effect sizes than pragmatic trials [18]. One main advan-
tage of stratified meta-regression methodology is that it
can help researchers and policy makers understand the
strength of evidence for efficacy and/or effectiveness of
an intervention in a population. It can also aid policy de-
cision making about an intervention when the direction
of pooled effect size in both pragmatic and explanatory
trials are in the same direction. However, policy decision
making about an intervention based on this stratified
meta-analysis approach may not always be straightfor-
ward especially when the estimated pooled intervention
effect sizes in both explanatory and pragmatic trials are
in opposite directions. Few studies have recommended
that policy decision making should be based on evidence
from pragmatic trials only since they confirm the real-
world effectiveness of an intervention [23, 24, 32]. But
this recommendation may not be valid when there is
limited number of pragmatic trials included in the
systematic review due to low statistical power.
Our comparisons of the meta-analytic methods for
synthesizing evidence from published trials rely on ob-
served data only. Future research will explore the use of
Monte Carlo methods to examine the statistical proper-
ties of these methods including their statistical power,
bias, mean square error, and coverage under a variety of
data analytic conditions. Importantly, the accuracy of the
pooled intervention effects obtained from meta-
regression analysis hinges on the accuracy of the
PRECIS-2 ratings to assess the degree of pragmatism in
each trial. While the ratings obtained from the three
reviewers in our study had good overall inter-rater
agreement, flexibility delivery and follow-up domains of
PRECIS-2 exhibited only moderate agreement. This is
consistent with previous studies that report high vari-
ability or poor agreement on flexibility and/or follow-up
domains [18, 19, 23, 24]. Additionally, we had missing
scores on some of the PRECIS domains for some studies
because the original articles lack this information. Al-
though Yoong et al. [18] recommend that investigators
should endeavor to contact primary authors of each
published trial with incomplete information when using
PRECIS-2, we did not contact authors of the original ar-
ticles but derived the mean scores on PRECIS domains
and overall score based on all the available scores [18,
19]. Future research will use sensitivity analysis to assess
the impact of missing data on estimates of pooled effect
sizes from meta-analytic investigations. Moreover, while
we have analyzed the overall PRECIS-2 scores for these
published trials, the component domains that constitute
this overall score may have ratings that vary on the
explanatory–pragmatic continuum. The PRECIS domain-
specific information about these trials might provide
policy makers with relevant information (e.g., about
implementation of interventions).
Conclusion
This study shows that the incorporation of information
about the type of trials (explanatory or pragmatic),
assessed using PRECIS-2 tool, can influence the estima-
tion of pooled intervention effects in meta-analysis of
published trials when there is substantial heterogeneity
Fig. 3 Comparison of meta-analytic methods for estimating overall intervention effect in trials for reducing obesity in children aged 6–12 years
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attributable to pragmatism. Secondly, this study also re-
veals the need for meta-regression methods that, adjusts
for PRECIS information as covariate, for estimating
pooled intervention effects in meta-analytic investiga-
tions. This ensures that valid conclusions are derived
from systematic reviews and meta-analysis of published
trials. We recommend that meta-analytic investigations
in systematic reviews should incorporate information
about design characteristics using PRECIS-2 when syn-
thesizing evidence from published studies.
Abbreviations
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